PF-04577806

• Description:

  PF-04577806 is a potent, selective and ATP competitive PKC inhibitor. PF-04577806 shows potent inhibitory activity towards PKCα, PKCβI, PKCβII, PKCγ, and PKCθ with IC50s of 2.4 nM, 8.1 nM, 6.9 nM, 45.9 nM, and 29.5 nM, respectively. PF-04577806 can reverse retinal vascular leakage in diabetic rats[1].

• UNSPSC:

  12352005

• Target:

  PKC; SHP2

• Type:

  Reference compound

• Related Pathways:

  Epigenetics; Protein Tyrosine Kinase/RTK; TGF-beta/Smad

• Applications:

  Metabolism-sugar/lipid metabolism

• Field of Research:

  Metabolic Disease

• Assay Protocol:

  https://www.medchemexpress.com/pf-04577806.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C(C1=CC=CC=N1)NC2=NNC3=C2CN(C(N4[C@H](CN([C@@H](C4)C)CC5CCOCC5)C)=O)C3(C)C

• Molecular Formula:

  C26H37N7O3

• Molecular Weight:

  495.62

• References & Citations:

  [1]Grant S, et, al. Discovery of a novel class of targeted kinase inhibitors that blocks protein kinase C signaling and ameliorates retinal vascular leakage in a diabetic rat model. Eur J Pharmacol. 2010 Feb 10;627 (1-3) :16-25.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  PKCα; PKCβ; PKCγ; PKCδ; PKCε; PKCθ

• CAS Number:

  1072100-81-2